Investigating the results of transcatheter aortic valve implantation (TAVI) in non-diabetic and diabetic patients: a systematic review and meta-analysis DOI Creative Commons
Azam Soleimani,

Mahsa Maghsoodi,

Saeide Bahrani

et al.

BMC Cardiovascular Disorders, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 21, 2025

Transcatheter aortic valve implantation (TAVI) has emerged as an effective treatment option for patients with severe stenosis, particularly in those who are not suitable candidates open-heart surgery. While diabetes is known to be associated a higher risk of cardiovascular diseases, the impact on outcomes TAVI remains controversial. A systematic literature search was conducted across major databases, including PubMed, Web Science (WOS), and Google Scholar, studies published English over past 20 years, up until July 2024. total 10 observational were analyzed, revealing that diabetic generally younger than non-diabetic patients. The 30-day mortality rate lower non-diabetics (0.03 [0.02–0.04]) compared diabetics (0.04 [0.03–0.05]). However, hazard ratio death beyond 30 days 2.05 (95% CI: 0.91–4.60, p = 0.08), at one year, it 1.04 0.78–1.39, 0.77), neither result reaching statistical significance. Meta-regression analysis showed non-insulin-treated significantly increased acute kidney injury (AKI) non-diabetics, log odds (LogOR) 0.3393 (p 0.035) 0.3166 0.028) another, confirming statistically significant increase AKI risk. This review highlights while slightly increases short-term after TAVI, long-term survival comparable raises (AKI), emphasizing need enhanced renal protection perioperative management. Not applicable.

Language: Английский

Investigating the results of transcatheter aortic valve implantation (TAVI) in non-diabetic and diabetic patients: a systematic review and meta-analysis DOI Creative Commons
Azam Soleimani,

Mahsa Maghsoodi,

Saeide Bahrani

et al.

BMC Cardiovascular Disorders, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 21, 2025

Transcatheter aortic valve implantation (TAVI) has emerged as an effective treatment option for patients with severe stenosis, particularly in those who are not suitable candidates open-heart surgery. While diabetes is known to be associated a higher risk of cardiovascular diseases, the impact on outcomes TAVI remains controversial. A systematic literature search was conducted across major databases, including PubMed, Web Science (WOS), and Google Scholar, studies published English over past 20 years, up until July 2024. total 10 observational were analyzed, revealing that diabetic generally younger than non-diabetic patients. The 30-day mortality rate lower non-diabetics (0.03 [0.02–0.04]) compared diabetics (0.04 [0.03–0.05]). However, hazard ratio death beyond 30 days 2.05 (95% CI: 0.91–4.60, p = 0.08), at one year, it 1.04 0.78–1.39, 0.77), neither result reaching statistical significance. Meta-regression analysis showed non-insulin-treated significantly increased acute kidney injury (AKI) non-diabetics, log odds (LogOR) 0.3393 (p 0.035) 0.3166 0.028) another, confirming statistically significant increase AKI risk. This review highlights while slightly increases short-term after TAVI, long-term survival comparable raises (AKI), emphasizing need enhanced renal protection perioperative management. Not applicable.

Language: Английский

Citations

0